Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among […]
